Light the Way Forward Grant

Funder: The Sumaira Foundation Inc (Brookline, MA) in partnership with Viela Bio

Focus Area: Research to improve understanding of Neuromyelitis Optica Spectrum Disorder (NMOSD) and positively impact those living with NMOSD

Geographic Scope: United States

Eligibility:

• Clinical, translational, and basic researchers with experience in NMOSD and related conditions
• Must be affiliated with academic institutions in the United States

Award Details:

• Up to $25,000 per grant
• Award granted to researcher's institution
• First-ever medical grant from Viela Bio (established 2021)

Special Characteristics:

• Made possible by research grant from Viela Bio
• Continuation of partnership between TSF and Viela Bio
• Partnership between industry and rare disease advocacy community

Research Focus:
Research aimed at improving understanding of NMOSD pathogenesis, diagnosis, and treatment outcomes

Post-Award Requirements:

• Mid-term project report required
• Final completion report required

Contact:

• Address: The Sumaira Foundation, PO Box 161, Brookline, MA 02446
• Website: sumairafoundation.org

Background:

• Viela Bio received FDA approval for Uplizna® (inebilizumab-cdon) for NMOSD treatment in June 2020
• The Sumaira Foundation is a 501(c)(3) organization founded by an NMO patient dedicated to generating global awareness of NMOSD, fundraising to find a cure, and creating community support for patients and caregivers

Application Instructions

Required Materials:

• Two-page project summary
• Budget information (funding secured and requested)
• List of personnel
• Curriculum Vitae (CV)

Submission Process:

1. Prepare two-page project summary including budget and personnel information
2. Include current CV
3. Submit through online application portal

Note: Specific application timeline and deadline not provided in available documentation. Contact TSF for current deadline.